I think hottod is right that 1) pursuing a Ph III PMS alone would be risky (requiring most of their existing cash and income) and 2) that partnering for PMS or licensing it out would muddy the waters for a future T/O (a large acquirer would prefer an asset not already encumbered to other parties).
However, as others have mentioned, there's still the 3rd way, external funding from a party like Blackrock. This would allow Neuren to access much more cash (several Ph 3s? lots more Ph 2s?), reduce the risks, and also avoid complications for an eventual T/O. The assumption would be that the funding party would be along for the T/O and cooperate with it. In fact, it would be the reason they're involved - their goal is a full 'exit' in a few years.
This move would dilute the eventual return with the 3rd party obviously getting a % of any final deal for their support. However, so long as you can see how giving up 15-25% equity (or agreeing to the funding party taking a similarly structured 'fee' in a T/O) now would help you increase the final T/O price by at least this 15-25% (something likely easy to argue for) then this could be an easy decision.
Funding is normally expensive. However, Neuren's in a great position with an on-market product, strong pipeline, positive cashflows and likely a relatively short time frame to exit (maybe 2-3 years, unlike a biotech startup with an exit 10 years away). Neuren would be able to drive a deal on favourable terms. In fact, I could imagine parties like Blackrock falling over themselves to assist in funding such a high quality opportunity.
As we know, there's already been a few comments from Jon & others hinting that such an arrangement may be under consideration.
- Forums
- ASX - By Stock
- Ann: 2023 Annual Report to shareholders
I think hottod is right that 1) pursuing a Ph III PMS alone...
- There are more pages in this discussion • 116 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.70 |
Change
0.520(2.71%) |
Mkt cap ! $2.515B |
Open | High | Low | Value | Volume |
$19.39 | $19.84 | $19.28 | $5.675M | 288.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 1531 | $19.66 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.81 | 557 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 72 | 19.250 |
1 | 260 | 19.180 |
1 | 150 | 19.000 |
1 | 50 | 18.900 |
1 | 2750 | 18.830 |
Price($) | Vol. | No. |
---|---|---|
19.810 | 557 | 1 |
19.850 | 700 | 1 |
20.000 | 6268 | 9 |
20.130 | 250 | 1 |
20.180 | 523 | 1 |
Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
Last
$19.70 |
  |
Change
0.520 ( 2.59 %) |
|||
Open | High | Low | Volume | ||
$19.50 | $19.84 | $19.28 | 87628 | ||
Last updated 15.59pm 03/05/2024 ? |
Featured News
NEU (ASX) Chart |